Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. The conglomerate’s investment—which collectively ...
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a $10 million USD investment from Samsung ...
C2N Diagnostics has received a $10m strategic investment out of Samsung’s life science investment fund. The US company said the cash injection would help to scale its clinical laboratory services and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results